Chemerin, omentin-1 and miR-103p and their relationship with gestational diabetes mellitus
PDF (Español (España))
HTML (Español (España))


adipose tissue

How to Cite

Sosa García, B. C., Mendieta Zerón, H., Hinojosa Suárez, A. C., & García, M. C. (2020). Chemerin, omentin-1 and miR-103p and their relationship with gestational diabetes mellitus. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(1), 20–28.


Several genes can trigger gestational diabetes mellitus (GDM), considered a public health problem of complex and multifactorial etiology.
Objective: To present a topic review of the available scientific evidence regarding the impact of omentin-1, chemerin and miR-1013p gene expression in the development of GDM.
Materials and methods: A search of studies published during 2010-2019 about the three genes in women with GDM was carried out through MEDLINE and PUBMED.
Results: Eight articles met the inclusion criteria: four articles measured chemerin levels, three omentin-1 and one miR103p. It was shown that the circulation of chemerin and miR103p were positively correlated with the metabolic variables during the first and third trimester of pregnancy, it was also demonstrated that the omentin-1 release was higher in adipose tissue vs. placenta in cases of obesity.
Conclusion: Chemerin and miR-103p expression seems to related with the development of GDM
PDF (Español (España))
HTML (Español (España))


1. Flores L, Solorio I, Melo M, Trejo J. Embarazo y obesidad: riesgo para desarrollo de diabetes gestacional en la frontera norte de México. Gac Méd Méx. 2014;150,73-8.
2. Farias J, Pérez C, Saavedra D. Diabetes mellitus gestacional: una aproximación a los conceptos actuales sobre estrategias diagnósticas. Rev Fac Med. 2016;64(4):769-75.
3. Zárate A, Saucedo R, Basurto L, Hernández M. El nuevo enfoque hacia la diabetes gestacional. Rev Med Inst Mex Seguro Soc. 2011;49(1):1-3.
4. Bakris G, Blonde L, Boulton A. Standards of medical care in diabetes. 2018. J Clin Appl Res Educ. 2018;41(1):S1-159.
5. Arroyo L, Burbaro J. Diabetes y pie diabético: una problemática mundial abordada desde la fisioterapia. Rev Colomb Endocrinol Diabetes y Metab. 2019;6(3):199-208.
6. Márquez G. Consenso Latinoamericano de Diabetes y Embarazo. Asoc Latinoam Diabetes. 2007;1-14.
7. Instituto Nacional de Salud Pública. Encuesta nacional de salud y nutrición de medio camino 2016. Informe Final de Resultados. 2016.
8. Gastaldelli A, Gaggini M, De Defronzo R. Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio metabolism study. Diabetes. 2017;66:815-22.
9. Atégbo M, Grissa A, Hichami K, Dramane L, Mountairou K, Miled A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006;91(10):4137-43.
10. Roll J, González N. Diabetes y obesidad: estudio en un área de salud. Rev Cubana Med Gen Integr. 2005;21,5-6.
11. de Gennaro G, Palla G, Battini L, Simoncini T, Prato S, Bertolotto A, et al. The role of adipokines in the pathogenesis of gestational diabetes mellitus. Gynecol Endocrinol. 2019;35(9):737-51.
12. Jayabalan N, Nair S, Nuzhat Z, Rice G, Zuñiga F, Lappas M. Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes. Front Endocrinol (Lausanne). 2017;8:239.
13. Benton M, Danielson K, Jones A, Macartney D, Das S, Ziegler O, et al. miRNA signatures of insulin resistance in obesity. Obesity. 2017;25(10):1734-44.
14. Samad F, Yamamoto K, Pandey M, Loskutoff D. Elevated expression of transforming growth factor- 3 in adipose tissue from obese mice. Mol Med. 1997;3(1):37-48.
15. Saleh J, Wahab R, Farhan H, Al-amri I, Cianflone K. Plasma levels of acylation-stimulating protein are strongly predicted by waist/hip ratio and correlate with decreased LDL size in men. ISRN Obes. 2013;(2013):1-6.
16. Goralski K, McCarthy T, Hanniman E, Zabel B, Parlee S, Muruganandan S, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282(38):28175-88.
17. Arana J, Carbó R, Hernández A, Sánchez F, Espinosa R. Omentina: papel en la resistencia a la insulina, inflamación y protección cardiovascular. Arch Cardiol Méx. 2015;86(3):233-43.
18. González F, Chávez A, Ramírez M, Pérez E, Moreno J, Saucedo M, et al. Quemerina en síndrome metabólico. El Residente. 2015;10(3):125-31.
19. van Poppel M, Ulrich D, Schest E, Hirschmugl B, Lang U, Wadsack C, et al. Cord blood chemerin: differential effects of gestational diabetes mellitus and maternal obesity. Endocrinol Clin. 2013;80(1)65-72.
20. Zarini GG, Exebio JC, Gundupalli D, Nath S, Huffman FG. Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes. Int J Nephrol Renovasc Dis. 2011;(4):35-40.
21. Sanchez J, López D, Pinzón A, Sepúlveda A. Adipocinas y síndrome metabólico: múltiples facetas de un proceso fisiopatológico complejo. Rev Colomb Cardiol. 2010;17(4):167-76.
22. De Souza C, Yang R, Lee M, Glynn N, Yu D, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-61.
23. Bork-Jensen B, Baun A, Bang-Bertelsen C, Grunnet L, Pociot F, Beck-Nielsen H, et al. Genetic versus non-genetic regulation of miR-103, miR-143 and miR-483-3p expression in adipose tissue and their metabolic implications - A twin study. Genes (Basel). 2014;5(3):508-17.
24. Pfau D, Fasshauer M, Stepan H, Drynda K, Lössner U, Verlohren M, et al. Circulating levels of the adipokine chemerin in gestational diabetes mellitus. Horm Res Paediatr. 2010;74(1):56-61.
25. Yang X, Quan X, Lan Y, Ye J, Wei Q, Yin X, et al. Serum chemerin level during the first trimester of pregnancy and the risk of gestational diabetes mellitus. Gynecol Endocrinol. 2017;33(10):770-3.
26. Cheon D, Kang J, Lee S, Ihm S, Lee E, Choi M, et al. Serum chemerin levels are associated with visceral adiposity, independent of waist circumference, in newly diagnosed type 2 diabetic subjects. Yonsei Med J. 2017;58(2):319-25.
27. Panayoula C, Panagiotis H, Konstantinos P, Eirini M, George S, Sotirios A, et al. Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus. Peptides. 2018;101:157-66.
28. Barker G, Lim R, Georgiou HM, Lappas M. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS One. 2012;7(8):1-8.
29. Abell SK, Shorakae S, Harrison C, Hiam D, Moreno A, Stepto N, et al. The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes. Diabetes Metab Res Rev. 2017;33(8):1-20.
30. Abell SK, Teede H, Boyle J, Stepto N, De Courten B, Harrison CL, et al. Role of serum biomarkers to optimise a validated clinical risk prediction tool for gestational diabetes. Aust New Zeal J Obstet Gynaecol. 2019;59(2):251-7.
31. Carreras-Badosa G, Bonmatí A, Ortega F, Mercader J, Guindo M, Torrents D, et al. Altered circulating miRNA expression profile in pregestational and gestational obesity. J Clin Endocrinol Metab. 2015;100(11):E1446-56.
32. Moher, D. Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA. Annals of Internal Medicine. 2009;151(4), 264. doi: 10.7326 / 0003-4819-151-4-200908180-00135.
33. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011;28:1194-200.
34. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes -2019. Diabetes Care. 2019;42(1):13-28.
35. Almeida E, Sabino C, Galváo I, Silva A, Grande I. Razón entre grasa visceral y subcutánea como predictor de alteraciones cardiometabólicas. Rev Chil Nut. 2018;45(1):28-36.
36. Tan B, Adya R, Farhatullah S, Lewandowski K, Hare P, Lehnert H, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Diabetes. 2008;57:801-8.
37. Coelho M, Oliveira T, Fernandes R. State of the art paper biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013.
38. Bozaoglu K, Curran J, Stocker C, Zaibi M, Segal D, Konstantopoulos N, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95(5):2476-85.
39. Álvarez G, Delgado J. Diseño de estudios epidemiológicos. I. El estudio transversal: tomando una fotografía de la salud y la enfermedad. Bol Clin Hosp Infant Edo Son. 2015;32(1):26-34.
40. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes Pregnancy study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):662-82.
41. Hulley S, Cummings S, Browner W, Grady D, Newman T. Delineando a pesquisa clínica. 4a edición. Porto Alegre: Artmed. 2015.
42. Martínez D. Qualis periódicos: el sistema brasileño de evaluación de revistas. Anuario ThinkEPI. 2019,13:1-12.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.